Skip to main content
. Author manuscript; available in PMC: 2012 Sep 29.
Published in final edited form as: Nature. 2012 Mar 18;483(7391):613–617. doi: 10.1038/nature10937

Figure 4. Long-term treatment outcome in Kras and Kras/p53 mice.

Figure 4

a, Tumour volume was longitudinally assessed by MRI imaging in Kras and Kras/p53 mice treated with either docetaxel or docetaxel plus selumetinib. Data points represent median tumour volume relative to start of treatment for all available data at the indicated time point. b, Progression-free survival for Kras mice treated with either docetaxel or docetaxel plus selumetinib. Median survival for single and combination treatments was 6 weeks and 12 weeks respectively, with ***P =0.0003 by log-rank test. c, Progression-free survival for Kras/p53 mice treated with either docetaxel or docetaxel plus selumetinib. Median survival for single and combination treatments was 2 weeks and 4 weeks, respectively, with ***P <0.0001 by log-rank test. Progression was defined as the time point when total tumour volume exceeded the baseline volume. d, Immunostaining of activation-specific phospho-ERK of tumours from Kras/p53 and Kras mice with acquired resistance to docetaxel and selumetinib treatment.